Please assess the completion status of the following clinical trial:

Trial Title: Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>35 week Gestational Age (GA) at birth~* \<3 months (90 days) old chronological age at the time of enrollment~* Exposed to a minimum five days of continuous narcotic infusion~Exclusion Criteria:~* Neurologic abnormality which would make Neonatal Abstinence Score (NAS) scoring inaccurate~* Major chromosomal abnormality (with the exception of Trisomy 21)~* Infant already enrolled in another randomized, controlled clinical trial

- Gender: ALL
- Minimum Age: 5 Days
- Maximum Age: 90 Days
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
- Control (Type: PLACEBO_COMPARATOR): Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally

Based on this trial design, predict the completion outcome and termination type (if applicable).